ADXN — Addex Therapeutics Cashflow Statement
0.000.00%
- CH₣4.96m
- CH₣1.65m
- CH₣1.65m
Annual cashflow statement for Addex Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.8 | -12.9 | -15.4 | -20.8 | -10.6 |
Depreciation | |||||
Non-Cash Items | 2.31 | 2.12 | 1.06 | 3.89 | 2.04 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.66 | -1.82 | -0.762 | 0.158 | 0.214 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -9.48 | -12.2 | -14.7 | -16.4 | -7.99 |
Capital Expenditures | -0.028 | -0.059 | -0.032 | -0.001 | -0.007 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.015 | 0 | 0.001 | 0.004 | 0 |
Sale of Fixed Assets | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.043 | -0.059 | -0.03 | 0.003 | -0.007 |
Financing Cash Flow Items | -0.153 | -0.306 | -2.33 | -0.599 | 1.06 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.464 | 0.046 | 16.4 | 3.1 | 5.26 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -10.1 | -12.8 | 1.79 | -13.5 | -3.09 |